A review of six placebo-controlled scientific trials with one,134 whole participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were being connected with a larger regular improvement on the Ashworth scale for spasticity in multiple sclerosis clients in contrast with placeb